The ODAC provides the FDA with independent opinions and review of safety and efficacy data from outside medical experts, though the recommendations are not binding. The FDA's evaluation of this ...

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; ...

A group led by researchers at the A.C.Camargo Cancer Center has succeeded in improving CAR-T cells, making them more ...

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...